Resting heart rate: Risk indicator and emerging risk factor in cardiovascular disease

American Journal of Medicine

Volumn 128, Issue 3, 2015, Pages 219-228

  Böhm, Michael ^a   Reil, Jan Christian ^a   Deedwania, Prakash ^b   Kim, Jae B ^c   Borer, Jeffrey S ^d  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMGEN INC   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angina; Heart failure; Heart rate; Ivabradine

Indexed keywords

BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; IVABRADINE;

CARDIOVASCULAR DISEASES; DRUG EFFECTS; HEART RATE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REST; RISK FACTOR; TREATMENT OUTCOME;

BENZAZEPINES; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HEART RATE; HUMANS; REST; RISK FACTORS; TREATMENT OUTCOME;

EID: 84924077422     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.09.016     Document Type: Review

References (131)

1. H.N. Sabbah, I. Ilsar, A. Zaretsky, S. Rastogi, M. Wang, and R.C. Gupta Vagus nerve stimulation in experimental heart failure Heart Fail Rev 16 2011 171 178
2. M. Böhm, and J.C. Reil Heart rate: surrogate or target in the management of heart failure? Heart 99 2013 72 75
3. M. Biel, C. Wahl-Schott, S. Michalakis, and X. Zong Hyperpolarization-activated cation channels: from genes to function Physiol Rev 89 2009 847 885
4. P. Palatini Elevated heart rate: A "new" cardiovascular risk factor? Prog Cardiovasc Dis 52 2009 1 5
5. R. Jurca, A.S. Jackson, and M.J. LaMonte Assessing cardiorespiratory fitness without performing exercise testing Am J Prev Med 29 2005 185 193
6. H.F. Brown, D. DiFrancesco, and S.J. Noble How does adrenaline accelerate the heart? Nature 280 1979 235 236
7. D. DiFrancesco, and J.A. Camm Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: A new therapeutic perspective in cardiovascular disease Drugs 64 2004 1757 1765
8. A.R. Dyer, V. Persky, and J. Stamler Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies Am J Epidemiol 112 1980 736 749
9. R.F. Gillum, D.M. Makuc, and J.J. Feldman Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study Am Heart J 121 1991 172 177
10. W.B. Kannel, C. Kannel, R.S. Paffenbarger Jr., and L.A. Cupples Heart rate and cardiovascular mortality: the Framingham Study Am Heart J 113 1987 1489 1494
11. B.N. Singh Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate J Cardiovasc Pharmacol Ther 6 2001 313 331
12. F. Custodis, J.C. Reil, U. Laufs, and M. Böhm Heart rate: A global target for cardiovascular disease and therapy along the cardiovascular continuum J Cardiol 62 2013 183 187
13. M.R. Carnethon, L. Yan, and P. Greenland Resting heart rate in middle age and diabetes development in older age Diabetes Care 31 2008 335 339
14. Y. Shigetoh, H. Adachi, and S. Yamagishi Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population Am J Hypertens 22 2009 151 155
15. R.L. Levy, P.D. White, W.D. Stroud, and C.C. Hillman Transcient tachycardia: prognostic significance alone and in association with transient hypertension JAMA 129 1945 585 588
16. P. Palatini, L. Thijs, and J.A. Staessen Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension Arch Intern Med 162 2002 2313 2321
17. L. Paul, C.E. Hastie, and W.S. Li Resting heart rate pattern during follow-up and mortality in hypertensive patients Hypertension 55 2010 567 574
18. P.M. Okin, S.E. Kjeldsen, and S. Julius All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy Eur Heart J 31 2010 2271 2279
19. R. Al Bannay, M. Böhm, and A. Husain Heart rate differentiates urgency and emergency in hypertensive crisis Clin Res Cardiol 102 2013 593 598
20. F. Custodis, S.H. Schirmer, M. Baumhäkel, G. Heusch, M. Böhm, and U. Laufs Vascular pathophysiology in response to increased heart rate J Am Coll Cardiol 56 2010 1973 1983
21. F. Custodis, M. Baumhäkel, and N. Schlimmer Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice Circulation 117 2008 2377 2387
22. M. Baumhäkel, F. Custodis, N. Schlimmer, U. Laufs, and M. Böhm Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice Atherosclerosis 212 2010 55 62
23. A. Drouin, M.E. Gendron, E. Thorin, M.A. Gillis, F. Mahlberg-Gaudin, and J.C. Tardif Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice Br J Pharmacol 154 2008 749 757
24. S.H. Schirmer, A. Degen, and M. Baumhakel Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis Eur Heart J 33 2012 1223 1231
25. D. Nanchen, D.J. Stott, and J. Gussekloo Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study Eur J Heart Fail 15 2013 581 588
26. B.O. Hartaigh, J.A. Bosch, and D. Carroll Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography Eur Heart J 34 2013 932 941
27. S.P. Whelton, R. Blankstein, and M.H. Al-Mallah Association of resting heart rate with carotid and aortic arterial stiffness: multi-ethnic study of atherosclerosis Hypertension 62 2013 477 484
28. H.S. Bassiouny, C.K. Zarins, M.H. Kadowaki, and S. Glagov Hemodynamic stress and experimental aortoiliac atherosclerosis J Vasc Surg 19 1994 426 434
29. Y.S. Chatzizisis, A.U. Coskun, M. Jonas, E.R. Edelman, C.L. Feldman, and P.H. Stone Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior J Am Coll Cardiol 49 2007 2379 2393
30. G.D. Giannoglou, Y.S. Chatzizisis, C. Zamboulis, G.E. Parcharidis, D.P. Mikhailidis, and G.E. Louridas Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms Int J Cardiol 126 2008 302 312
31. R. Nerla, A. Di Franco, and M. Milo Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients Heart 98 2012 1812 1816
32. U. Fischer-Rasokat, J. Honold, and D. Lochmann Ivabradine therapy to unmask heart rate-independent effects of beta-blockers on pulse wave reflections Clin Res Cardiol 103 2014 487 494
33. A. Perski, A. Hamsten, K. Lindvall, and T. Theorell Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients Am Heart J 116 1988 1369 1373
34. A. Perski, G. Olsson, C. Landou, U. de Faire, T. Theorell, and A. Hamsten Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age Am Heart J 123 1992 609 616
35. K. Fox, I. Ford, P.G. Steg, M. Tendera, and R. Ferrari BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial Lancet 372 2008 807 816
36. K. Fox, I. Ford, P.G. Steg, M. Tendera, M. Robertson, and R. Ferrari Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: A subgroup analysis of the randomized, controlled BEAUTIFUL trial Eur Heart J 30 2009 2337 2345
37. A. Hjalmarson, E.A. Gilpin, and J. Kjekshus Influence of heart rate on mortality after acute myocardial infarction Am J Cardiol 65 1990 547 553
38. S. Bangalore, G. Steg, and P. Deedwania Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease JAMA 308 2012 1340 1349
39. U.E. Heidland, and B.E. Strauer Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption Circulation 104 2001 1477 1482
40. E.M. Lonn, S. Rambihar, and P. Gao Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: An analysis of ONTARGET/TRANSCEND Clin Res Cardiol 103 2014 149 159
41. K. Fox, I. Ford, P.G. Steg, J.C. Tardif, M. Tendera, R. Ferrari the SIGNIFY Investigators Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure N Engl J Med 371 2014 1091 1099
42. R.J. Gibbons, J. Abrams, and K. Chatterjee ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina) J Am Coll Cardiol 41 2003 159 168
43. I. Graham, D. Atar, and K. Borch-Johnsen European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur Heart J 28 2007 2375 2414
44. G. Heusch Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents Br J Pharmacol 153 2008 1589 1601
45. J.S. Borer, K. Fox, P. Jaillon, G. Lerebours Ivabradine Investigators Group Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial Circulation 107 2003 817 823
46. J.C. Tardif, P. Ponikowski, T. Kahan, and A.S. Investigators Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: A 4-month, randomized, placebo-controlled trial Eur Heart J 30 2009 540 548
47. W. Ruzyllo, M. Tendera, I. Ford, and K.M. Fox Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: A 3-month randomised, double-blind, multicentre, noninferiority trial Drugs 67 2007 393 405
48. Task Force Members, G. Montalescot, and U. Sechtem 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Eur Heart J 34 2013 2949 3003
49. G. Heusch, A. Skyschally, P. Gres, P. van Caster, D. Schilawa, and R. Schulz Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction Eur Heart J 29 2008 2265 2275
50. J.J. McMurray, S. Adamopoulos, and S.D. Anker ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
51. M.A. Conway, J. Allis, R. Ouwerkerk, T. Niioka, B. Rajagopalan, and G.K. Radda Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy Lancet 338 1991 973 976
52. M. Böhm, K. La Rosee, U. Schmidt, C. Schulz, R.H. Schwinger, and E. Erdmann Force-frequency relationship and inotropic stimulation in the nonfailing and failing human myocardium: implications for the medical treatment of heart failure Clin Investig 70 1992 421 425
53. L.A. Mulieri, G. Hasenfuss, B. Leavitt, P.D. Allen, and N.R. Alpert Altered myocardial force-frequency relation in human heart failure Circulation 85 1992 1743 1750
54. G. Hasenfuss, C. Holubarsch, H.P. Hermann, K. Astheimer, B. Pieske, and H. Just Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy Eur Heart J 15 1994 164 170
55. D. Logeart, J.P. Gueffet, and F. Rouzet Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: A pilot study Eur J Heart Fail 11 2009 53 57
56. E. Umana, C.A. Solares, and M.A. Alpert Tachycardia-induced cardiomyopathy Am J Med 114 2003 51 55
57. P. Colin, B. Ghaleh, X. Monnet, L. Hittinger, and A. Berdeaux Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs J Pharmacol Exp Ther 308 2004 236 240
58. P.M. Becher, D. Lindner, and K. Miteva Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and beta-receptor blockade Hypertension 59 2012 949 957
59. E.I. Dedkov, W. Zheng, L.P. Christensen, R.M. Weiss, F. Mahlberg-Gaudin, and R.J. Tomanek Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen Am J Physiol Heart Circ Physiol 62 2007 H590
60. P. Milliez, S. Messaoudi, J. Nehme, C. Rodriguez, J.-L. Samuel, and C. Delcayre Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure Am J Physiol Heart Circ Physiol 296 2009 H435 H441
61. P. Mulder, S. Barbier, and A. Chagraoui Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure Circulation 109 2004 1674 1679
62. J.C. Tardif, E. O'Meara, and M. Komajda Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy Eur Heart J 32 2011 2507 2515
63. M. Böhm, K. Swedberg, and M. Komajda Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial Lancet 376 2010 886 894
64. P. Lechat, J.S. Hulot, and S. Escolano Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial Circulation 103 2001 1428 1433
65. G. Flannery, R. Gehrig-Mills, B. Billah, and H. Krum Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers Am J Cardiol 101 2008 865 869
66. F.A. McAlister, N. Wiebe, J.A. Ezekowitz, A.A. Leung, and P.W. Armstrong Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure Ann Intern Med 150 2009 784 794
67. K. Swedberg, M. Komajda, and M. Böhm Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study Lancet 376 2010 875 885
68. M. Böhm, J. Borer, and I. Ford Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study Clin Res Cardiol 102 2013 11 22
69. I. Ekman, O. Chassany, and M. Komajda Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study Eur Heart J 32 2011 2395 2404
70. J.C. Reil, J.C. Tardif, and I. Ford Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients J Am Coll Cardiol 62 2013 1977 1985
71. J.S. Borer, M. Böhm, and I. Ford Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study) Am J Cardiol 113 2014 497 503
72. L. Tavazzi, K. Swedberg, and M. Komajda Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study Eur J Heart Fail 15 2013 1296 1303
73. A.A. Voors, D.J. van Veldhuisen, and M. Robertson The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: An analysis from SHIFT Eur J Heart Fail 16 2014 426 434
74. J.C. Reil, M. Robertson, and I. Ford Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure Eur J Heart Fail 15 2013 1044 1052
75. L. Tavazzi, K. Swedberg, and M. Komajda Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study Int J Cardiol 170 2013 182 188
76. K. Swedberg, M. Komajda, and M. Böhm Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study J Am Coll Cardiol 59 2012 1938 1945
77. P. Abrahamsson, K. Swedberg, and J.S. Borer Risk following hospitalization in stable chronic systolic heart failure Eur J Heart Fail 15 2013 885 891
78. J.S. Borer, M. Böhm, and I. Ford Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study Eur Heart J 33 2012 2813 2820
79. K. Fox, M. Komajda, and I. Ford Effect of ivabradine in patients with left-ventricular systolic dysfunction: A pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials Eur Heart J 34 2013 2263 2270
80. J. Franke, J.S. Wolter, and L. Meme Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol 102 2013 23 31
81. M. Böhm, A.C. Perez, and P. Jhund Relationship between heart rate and mortality and morbidity in the irbesartan in patients with heart failure and preserved systolic function trial (I-Preserve) Eur J Heart Fail 16 2014 778 787
82. W. Kosmala, D.J. Holland, A. Rojek, L. Wright, M. Przewlocka-Kosmala, and T.H. Marwick Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: A randomized trial J Am Coll Cardiol 62 2013 1330 1338
83. D.J. van Veldhuisen, A. Cohen-Solal, and M. Bhm Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) J Am Coll Cardiol 53 2009 2150 2158
84. J.C. Reil, M. Hohl, and G.H. Reil Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction Eur Heart J 34 2013 2839 2849
85. D. Castagno, H. Skali, and M. Takeuchi Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program J Am Coll Cardiol 59 2012 1785 1795
86. J. Wilhelm, S. Hettwer, and M. Schuermann Elevated troponin in septic patients in the emergency department: frequency, causes, and prognostic implications Clin Res Cardiol 103 2014 561 567
87. J. Wilhelm, S. Hettwer, and M. Schuermann Severity of cardiac impairment in the early stage of community-acquired sepsis determines worse prognosis Clin Res Cardiol 102 2013 735 744
88. G. Azimi, and J.L. Vincent Ultimate survival from septic shock Resuscitation 14 1986 245 253
89. H. Schmidt, U. Müller-Werdan, and T. Hoffmann Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups Crit Care Med 33 2005 1994 2002
90. R.S. Hoke, U. Muller-Werdan, C. Lautenschlager, K. Werdan, and H. Ebelt Heart rate as an independent risk factor in patients with multiple organ dysfunction: A prospective, observational study Clin Res Cardiol 101 2012 139 147
91. G.L. Ackland, S.T. Yao, and A. Rudiger Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats Crit Care Med 38 2010 388 394
92. T. Suzuki, H. Morisaki, and R. Serita Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats Crit Care Med 33 2005 2294 2301
93. A. Morelli, C. Ertmer, and M. Westphal Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: A randomized clinical trial JAMA 310 2013 1683 1691
94. M.W. Dunser, and W.R. Hasibeder Sympathetic overstimulation during critical illness: Adverse effects of adrenergic stress J Intensive Care Med 24 2009 293 316
95. O. Sander, I.D. Welters, P. Foex, and J.W. Sear Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications Crit Care Med 33 2005 81 88 discussion 241-242
96. S. Nuding, H. Ebelt, and R.S. Hoke Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine: MODI (f)Y trial Clin Res Cardiol 100 2011 915 923
97. A. Link, J.C. Reil, S. Selejan, and M. Böhm Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure Clin Res Cardiol 98 2009 513 515
98. V. De Santis, D. Vitale, and A. Santoro Ivabradine: potential clinical applications in critically ill patients Clin Res Cardiol 102 2013 171 178
99. P.A. Beere, S. Glagov, and C.K. Zarins Retarding effect of lowered heart rate on coronary atherosclerosis Science 226 1984 180 182
100. U. Laufs, K. Gertz, U. Dirnagl, M. Böhm, G. Nickenig, and M. Endres Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice Brain Res 942 2002 23 30
101. V. Prinz, U. Laufs, and K. Gertz Intravenous rosuvastatin for acute stroke treatment: An animal study Stroke 39 2008 433 438
102. P. Angerer, U. Siebert, W. Kothny, D. Muhlbauer, H. Mudra, and C. von Schacky Impact of social support, cynical hostility and anger expression on progression of coronary atherosclerosis J Am Coll Cardiol 36 2000 1781 1788
103. P.G. Surtees, N.W. Wainwright, R.N. Luben, N.J. Wareham, S.A. Bingham, and K.T. Khaw Psychological distress, major depressive disorder, and risk of stroke Neurology 70 2008 788 794
104. F. Custodis, K. Gertz, and M. Balkaya Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice Stroke 42 2011 1742 1749
105. M. Böhm, D. Cotton, and L. Foster Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke Eur Heart J 33 2012 2804 2812
106. M. Böhm, H. Schumacher, and D. Leong Systolic blood pressure variability and heart rate predict new onset of cognitive dysfunction and cognitive decline in patients with high cardiovascular risk Hypertension 2015; In press
107. G. Remuzzi, and T. Bertani Pathophysiology of progressive nephropathies N Engl J Med 339 1998 1448 1456
108. R.E. Schmieder, J. Schrader, and W. Zidek Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 96 2007 247 257
109. M. Böhm, J.C. Reil, N. Danchin, M. Thoenes, P. Bramlage, and M. Volpe Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH J Hypertens 26 2008 18 25
110. M. Böhm, M. Thoenes, and H.R. Neuberger Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients Eur Heart J 30 2009 1364 1371
111. R. Loutzenhiser, A. Bidani, and L. Chilton Renal myogenic response: kinetic attributes and physiological role Circ Res 90 2002 1316 1324
112. G.S. Hill, D. Heudes, C. Jacquot, E. Gauthier, and J. Bariety Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension Kidney Int 69 2006 823 831
113. T.H. Hostetter, H.G. Rennke, and B.M. Brenner The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies Am J Med 72 1982 375 380
114. R. Loutzenhiser, K. Griffin, G. Williamson, and A. Bidani Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms Am J Physiol Regul Integr Comp Physiol 290 2006 R1153 1167
115. G.S. Hillis, J. Hata, and M. Woodward Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus J Am Heart Assoc 1 2012 e002832
116. M. Böhm, H. Schumacher, and R. Schmieder Renal outcomes are independently associated with resting heart rate in patients with vascular disease: results of the ONTARGET and TRANSCEND studies J Int Med 2014; In press
117. H.A. Feldman, I. Goldstein, D.G. Hatzichristou, R.J. Krane, and J.B. McKinlay Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study J Urol 151 1994 54 61
118. H. Solomon, J.W. Man, and G. Jackson Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator Heart 89 2003 251 253
119. M. Baumhäkel, and M. Böhm Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients Int J Clin Pract 61 2007 361 366
120. R.C. Ma, W.Y. So, and X. Yang Erectile dysfunction predicts coronary heart disease in type 2 diabetes J Am Coll Cardiol 51 2008 2045 2050
121. M. Böhm, M. Baumhäkel, and K. Teo Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials Circulation 121 2010 1439 1446
122. M.T. Kratz, H. Schumacher, and K. Sliwa Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients Eur J Prev Cardiol 21 2014 272 280
123. M.T. Jensen, J.L. Marott, and P. Lange Resting heart rate is a predictor of mortality in COPD Eur Respir J 42 2013 341 349
124. V.V. Georgiopoulou, S. Dimopoulos, and D. Sakellariou Cardiopulmonary rehabilitation enhances heart rate recovery in patients with COPD Respir Care 57 2012 2095 2103
125. E. Gimeno-Santos, D.A. Rodriguez, and A. Barberan-Garcia Endurance exercise training improves heart rate recovery in patients with COPD COPD 11 2014 190 196
126. I.R. Henkens, S.A. Van Wolferen, and C.T. Gan Relation of resting heart rate to prognosis in patients with idiopathic pulmonary arterial hypertension Am J Cardiol 103 2009 1451 1456
127. M. Correale, D. Montrone, R. Ieva, M. Di Biase, and N.D. Brunetti Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy? Clin Res Cardiol 102 2013 391 393
128. M. Correale, D. Montrone, M.D. Biase, and N.D. Brunetti Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension Clin Res Cardiol 101 2012 593 594
129. R. Cappato, S. Castelvecchio, and C. Ricci Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: A prospective, randomized, placebo-controlled, double-blind, crossover evaluation J Am Coll Cardiol 60 2012 1323 1329
130. K. Werdan, H. Ebelt, S. Nuding, F. Hopfner, G. Hack, and U. Muller-Werdan Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study Clin Res Cardiol 101 2012 365 373
131. J.C. Reil, and M. Böhm BEAUTIFUL results-the slower, the better? Lancet 372 2008 779 780